Jon George, MD
Interventional Cardiology · Philadelphia, PANPI 1992746721
Payments from drug & device makers
Across 1,438 payments — averaging $506.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$175K
- Siemens Medical Solutions USA, Inc.$139K
- Cardiovascular Systems Inc.$62K
- Amplitude Vascular Systems, Inc.$57K
- Penumbra, Inc.$56K
- Philips North America LLC$34K
- plus $205K from 53 others
Across 2 payments — averaging $6732.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$13K
What the payments were for
- Consulting fees$212,15533%
- Speaking & faculty fees$260,30641%
- Travel & lodging$107,09117%
- Food & beverage$49,8938%
- Education$6,3431%
- Other$9580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$64,168
- Indigo System$54,775
- HawkOne$43,528
- Impella$21,980
- Diamondback Peripheral$19,958
- PANTHERIS$18,894
- GENERAL VASCULAR ACCESS$15,750
- Artis icono floor$15,013
- CorPath GRX$14,633
- ClosureFast$11,800
- Abre$11,353
- Diamondback Coronary$11,134
- Coronary Orbital Atherectomy System$10,870
- ANGIOGUARD RX Emboli Capture Guidewire System$10,000
- PRECISE PRO RX Carotid Stent System$10,000
- CorPath Imaging System$8,620
- TurboHawk$7,611
- (9520) IGT Devices Undivided$7,509
- GENERAL - THERAPIES$6,715
- IVUS Systems$6,600
How this compares
$727,829 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $62,485 |
| EntrestoSacubitril/Valsartan | 44 | $36,982 |
| XareltoRivaroxaban | 22 | $22,506 |
| FarxigaDapagliflozin Propanediol | 24 | $20,621 |
| BrilintaTicagrelor | 12 | $6,866 |
| ClopidogrelClopidogrel Bisulfate | 157 | $2,095 |
| Atorvastatin Calcium | 109 | $1,744 |
| Metoprolol Succinate | 114 | $1,674 |
| Losartan Potassium | 88 | $1,071 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $771 |
| Amlodipine Besylate | 73 | $747 |
| Lisinopril | 58 | $668 |
| Carvedilol | 60 | $530 |
| Cilostazol | 25 | $398 |
| Nitroglycerin | 17 | $275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $62,48559 claims |
| NovartisEntresto | $186 | $36,98244 claims |
| AstraZenecaFarxiga, Brilinta | $235 | $27,48736 claims |
| Johnson & JohnsonXarelto | $146 | $22,50622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Philadelphia
- Howard HerrmannPhiladelphia$2.2M
- Jay GiriPhiladelphia$1M
- Sameer KhandharPhiladelphia$831K
- Taisei KobayashiPhiladelphia$473K
- Sanjog KalraPhiladelphia$462K
- Ashwin NathanPhiladelphia$328K
- Gene ChangPhiladelphia$217K
- Sahil BankaPhiladelphia$148K
- Paul FiorilliPhiladelphia$134K
- Oleg VishnevskyPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.